TPN171 is a selective and oral bioavailable phosphodiesterase type 5 (PDE5) inhibitor (IC50: 0.62 nM), which has the potential for the treatment of pulmonary arterial hypertension (PAH).

1229018-87-4

C24H35N5O3

441.57

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years